메뉴 건너뛰기




Volumn 1, Issue 5, 2010, Pages 234-238

Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZYLOXYCARBONYL; ALBUMIN; ARGINYLSERYLSERYLTYROSYLTYROSYLSERYLLEUCINE; BENZYL DERIVATIVE; CARBONYL DERIVATIVE; CYSTEINE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; HEPTAPEPTIDE; HUMAN SERUM ALBUMIN; PRODRUG; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

EID: 77956154259     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100060m     Document Type: Article
Times cited : (40)

References (25)
  • 1
    • 43449127502 scopus 로고    scopus 로고
    • Prostate cancer
    • Damber, J. E.; Aus, G. Prostate cancer Lancet 2008, 371, 1710-1721
    • (2008) Lancet , vol.371 , pp. 1710-1721
    • Damber, J.E.1    Aus, G.2
  • 2
    • 40149099162 scopus 로고    scopus 로고
    • Chemotherapy in hormone-refractory prostate cancer
    • de Wit, R. Chemotherapy in hormone-refractory prostate cancer BJU Int. 2008, 101 (Suppl. 2) 11-15
    • (2008) BJU Int. , vol.101 , Issue.SUPPL. 2 , pp. 11-15
    • De Wit, R.1
  • 5
    • 56949084877 scopus 로고    scopus 로고
    • Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
    • Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183
    • (2008) J. Controlled Release , vol.132 , pp. 171-183
    • Kratz, F.1
  • 6
    • 0034000453 scopus 로고    scopus 로고
    • Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
    • Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review J. Controlled Release 2000, 65, 271-284
    • (2000) J. Controlled Release , vol.65 , pp. 271-284
    • Maeda, H.1    Wu, J.2    Sawa, T.3    Matsumura, Y.4    Hori, K.5
  • 7
    • 0037028050 scopus 로고    scopus 로고
    • Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
    • Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Drückes, P.; Esser, N.; Drevs, J.; Rognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 2002, 45, 5523-5533
    • (2002) J. Med. Chem. , vol.45 , pp. 5523-5533
    • Kratz, F.1    Warnecke, A.2    Scheuermann, K.3    Stockmar, C.4    Schwab, J.5    Lazar, P.6    Drückes, P.7    Esser, N.8    Drevs, J.9    Rognan, D.10    Bissantz, C.11    Hinderling, C.12    Folkers, G.13    Fichtner, I.14    Unger, C.15
  • 8
    • 0042173127 scopus 로고    scopus 로고
    • A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
    • Mansour, A. M.; Drevs, J.; Esser, N.; Hamada, F. M.; Badary, O. A.; Unger, C.; Fichtner, I.; Kratz, F. A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 Cancer Res. 2003, 63, 4062-4066
    • (2003) Cancer Res. , vol.63 , pp. 4062-4066
    • Mansour, A.M.1    Drevs, J.2    Esser, N.3    Hamada, F.M.4    Badary, O.A.5    Unger, C.6    Fichtner, I.7    Kratz, F.8
  • 9
    • 34249980937 scopus 로고    scopus 로고
    • DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials
    • Kratz, F. DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866
    • (2007) Expert Opin. Invest. Drugs , vol.16 , pp. 855-866
    • Kratz, F.1
  • 10
    • 34347354414 scopus 로고    scopus 로고
    • Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
    • Schmid, B.; Chung, D. E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716
    • (2007) Bioconjugate Chem. , vol.18 , pp. 702-716
    • Schmid, B.1    Chung, D.E.2    Warnecke, A.3    Fichtner, I.4    Kratz, F.5
  • 11
    • 33747339731 scopus 로고    scopus 로고
    • Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)
    • Chung, D. E.; Kratz, F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA) Bioorg. Med. Chem. Lett. 2006, 16, 5157-5163
    • (2006) Bioorg. Med. Chem. Lett. , vol.16 , pp. 5157-5163
    • Chung, D.E.1    Kratz, F.2
  • 12
    • 27644436770 scopus 로고    scopus 로고
    • Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA)
    • Kratz, F.; Mansour, A.; Soltau, J.; Warnecke, A.; Fichtner, I.; Unger, C.; Drevs, J. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA) Arch. Pharm. 2005, 338, 462-472
    • (2005) Arch. Pharm. , vol.338 , pp. 462-472
    • Kratz, F.1    Mansour, A.2    Soltau, J.3    Warnecke, A.4    Fichtner, I.5    Unger, C.6    Drevs, J.7
  • 13
    • 38749154289 scopus 로고    scopus 로고
    • Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP)
    • Graeser, R.; Chung, D. E.; Esser, N.; Moor, S.; Schachtele, C.; Unger, C.; Kratz, F. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP) Int. J. Cancer 2008, 122, 1145-1154
    • (2008) Int. J. Cancer , vol.122 , pp. 1145-1154
    • Graeser, R.1    Chung, D.E.2    Esser, N.3    Moor, S.4    Schachtele, C.5    Unger, C.6    Kratz, F.7
  • 14
    • 34548067350 scopus 로고    scopus 로고
    • Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
    • Warnecke, A.; Fichtner, I.; Sass, G.; Kratz, F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B Arch. Pharm. (Weinheim) 2007, 340, 389-395
    • (2007) Arch. Pharm. (Weinheim) , vol.340 , pp. 389-395
    • Warnecke, A.1    Fichtner, I.2    Sass, G.3    Kratz, F.4
  • 15
    • 0023622310 scopus 로고
    • The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein
    • Akiyama, K.; Nakamura, T.; Iwanaga, S.; Hara, M. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein FEBS Lett. 1987, 225, 168-172
    • (1987) FEBS Lett. , vol.225 , pp. 168-172
    • Akiyama, K.1    Nakamura, T.2    Iwanaga, S.3    Hara, M.4
  • 16
    • 0028918466 scopus 로고
    • New diagnostic applications and physiological functions of prostate specific antigen
    • Diamandis, E. P. New diagnostic applications and physiological functions of prostate specific antigen Scand. J. Clin. Lab. Invest. Suppl. 1995, 221, 105-112
    • (1995) Scand. J. Clin. Lab. Invest. Suppl. , vol.221 , pp. 105-112
    • Diamandis, E.P.1
  • 17
    • 0035876331 scopus 로고    scopus 로고
    • Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
    • Denmeade, S. R.; Sokoll, L. J.; Chan, D. W.; Khan, S. R.; Isaacs, J. T. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate 2001, 48, 1-6
    • (2001) Prostate , vol.48 , pp. 1-6
    • Denmeade, S.R.1    Sokoll, L.J.2    Chan, D.W.3    Khan, S.R.4    Isaacs, J.T.5
  • 18
    • 0030991964 scopus 로고    scopus 로고
    • Free/total prostate-specific antigen ratio - Hope and controversies
    • Ravery, V.; Boccon-Gibod, L. Free/total prostate-specific antigen ratio - Hope and controversies Eur. Urol. 1997, 31, 385-388
    • (1997) Eur. Urol. , vol.31 , pp. 385-388
    • Ravery, V.1    Boccon-Gibod, L.2
  • 19
    • 0031813782 scopus 로고    scopus 로고
    • Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer
    • Denmeade, S. R.; Isaacs, J. T. Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer Cancer J. Sci. Am. 1998, 4 (Suppl. 1) S15-S21
    • (1998) Cancer J. Sci. Am. , vol.4 , Issue.SUPPL. 1
    • Denmeade, S.R.1    Isaacs, J.T.2
  • 21
    • 0033843895 scopus 로고    scopus 로고
    • In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts
    • Khan, S. R.; Denmeade, S. R. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate 2000, 45, 80-83
    • (2000) Prostate , vol.45 , pp. 80-83
    • Khan, S.R.1    Denmeade, S.R.2
  • 23
    • 0032402354 scopus 로고    scopus 로고
    • Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin
    • Dubowchik, G. M.; Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346
    • (1998) Bioorg. Med. Chem. Lett. , vol.8 , pp. 3341-3346
    • Dubowchik, G.M.1    Firestone, R.A.2
  • 24
    • 0033814795 scopus 로고    scopus 로고
    • Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor
    • Malm, J.; Hellman, J.; Hogg, P.; Lilja, H. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor Prostate 2000, 45, 132-139
    • (2000) Prostate , vol.45 , pp. 132-139
    • Malm, J.1    Hellman, J.2    Hogg, P.3    Lilja, H.4
  • 25
    • 77956168233 scopus 로고    scopus 로고
    • A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases
    • submitted for publication
    • Elsadek, B.; Graeser, R.; Esser, N.; Schäfer-Obodozie, C.; Tsurumi, C. A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases. Int. J. Cancer 2010, submitted for publication.
    • (2010) Int. J. Cancer
    • Elsadek, B.1    Graeser, R.2    Esser, N.3    Schäfer-Obodozie, C.4    Tsurumi, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.